Quality of Life in Electrochemotherapy for Cutaneous and Mucosal Head and Neck Tumors.
electrochemotherapy
head and neck cancer
quality of life
skin cancer
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
24 Sep 2021
24 Sep 2021
Historique:
received:
03
08
2021
revised:
18
09
2021
accepted:
21
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Primary or recurrent head and neck cancer of skin or mucosa represents a challenge for clinicians and could be debilitating for the patient. Electrochemotherapy (ECT) emerged as a local ablative procedure for cutaneous and mucosal head and neck tumors. The aim of this observational study was the evaluation of quality of life (QoL) after ECT in patients without other surgical or radiation options as curative treatment. The procedure was performed according the ESOPE (European Standard Operating procedure of Electrochemotherapy) protocol. Twenty-seven patients were evaluated before ECT (T0) and 1 (T1), 3 (T2), and 6 (T3) months after the procedure. QoL was assessed by means of the EORTC QLQ-C30 and EORTC QLQ-H&N35 questionnaires. The objective tumor response rate was 48% (11% CR, 37% PR). Bleeding control was achieved in 7/7 patients who experienced bleeding prior to ECT. QoL improvement was observed after the procedure. In particular, global health status and social functioning were higher after ECT ( ECT represents a safe and effective treatment for skin and mucosal head and neck tumors without other curative options. It ensures a good pain and bleeding control without worsening of QoL.
Sections du résumé
BACKGROUND
BACKGROUND
Primary or recurrent head and neck cancer of skin or mucosa represents a challenge for clinicians and could be debilitating for the patient. Electrochemotherapy (ECT) emerged as a local ablative procedure for cutaneous and mucosal head and neck tumors. The aim of this observational study was the evaluation of quality of life (QoL) after ECT in patients without other surgical or radiation options as curative treatment.
MATERIALS AND METHODS
METHODS
The procedure was performed according the ESOPE (European Standard Operating procedure of Electrochemotherapy) protocol. Twenty-seven patients were evaluated before ECT (T0) and 1 (T1), 3 (T2), and 6 (T3) months after the procedure. QoL was assessed by means of the EORTC QLQ-C30 and EORTC QLQ-H&N35 questionnaires.
RESULTS
RESULTS
The objective tumor response rate was 48% (11% CR, 37% PR). Bleeding control was achieved in 7/7 patients who experienced bleeding prior to ECT. QoL improvement was observed after the procedure. In particular, global health status and social functioning were higher after ECT (
CONCLUSION
CONCLUSIONS
ECT represents a safe and effective treatment for skin and mucosal head and neck tumors without other curative options. It ensures a good pain and bleeding control without worsening of QoL.
Identifiants
pubmed: 34640382
pii: jcm10194366
doi: 10.3390/jcm10194366
pmc: PMC8509577
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancers (Basel). 2021 Mar 12;13(6):
pubmed: 33809141
Eur J Cancer. 2016 Jul;62:138-45
pubmed: 27237360
Head Neck. 2019 Feb;41(2):329-339
pubmed: 30552847
Oral Oncol. 2019 May;92:77-84
pubmed: 31010628
Acta Oncol. 2018 Jul;57(7):874-882
pubmed: 29577784
Expert Rev Anticancer Ther. 2020 Jan;20(1):17-29
pubmed: 31899993
J Craniomaxillofac Surg. 2019 Jan;47(1):41-46
pubmed: 30471938
Drug Des Devel Ther. 2015 Feb 19;9:1185-91
pubmed: 25733822
Eur J Cancer. 1991;27(1):68-72
pubmed: 1707289
Eur J Cancer. 2016 Aug;63:41-52
pubmed: 27267144
Eur J Cancer. 2017 Dec;87:172-181
pubmed: 29156298
Semin Oncol. 2014 Dec;41(6):798-806
pubmed: 25499638
Eur J Cancer. 2019 Jan;107:153-163
pubmed: 30576971
Cancers (Basel). 2021 Mar 19;13(6):
pubmed: 33808884
Cancers (Basel). 2021 May 04;13(9):
pubmed: 34064511
Oral Oncol. 2012 Oct;48(10):923-937
pubmed: 22525604
Eur J Cancer. 2020 Oct;138:30-40
pubmed: 32836172
Anticancer Res. 2015 Nov;35(11):6247-54
pubmed: 26504058
Anticancer Drugs. 1998 Apr;9(4):319-25
pubmed: 9635922